At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $241.97, up 2.20%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALNY shares have gain 4.78% over the last week, with a monthly amount drifted -16.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $353. Previously, JP Morgan upgraded its rating to Overweight on March 24, 2025, and elevated its price target to $328. On November 12, 2024, downgrade downgraded it’s rating to Underperform. Scotiabank started tracking the stock assigning a Sector Outperform rating. Goldman upgraded its rating to a Buy and raised its price target to $370 on August 16, 2024. Goldman downgraded its rating to Neutral for this stock on February 16, 2024, but kept the price target unchanged to $173. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $328 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $241.97 at the most recent close of the market. An investor can expect a potential return of 35.55% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.25B for trailing twelve months, which represents an 34.90% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.08%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is 9.05 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 19.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 238.46 points at the first support level, and at 234.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 247.04, and for the 2nd resistance point, it is at 252.10.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.78. As well, the Quick Ratio is 2.71, while the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 14.00, the price to book ratio is 466.33.
Transactions by insiders
Recent insider trading involved Garg Pushkal, CMO & EVP Dev & Med Affairs, that happened on Mar 24 ’25 when 5445.0 shares were sold. CMO & EVP Dev & Med Affairs, Garg Pushkal completed a deal on Mar 21 ’25 to sell 4321.0 shares. Meanwhile, Director PYOTT DAVID E I sold 7440.0 shares on Mar 24 ’25.
